Search

everythinglearnresearchcommunity

for

Search:↓

A Spanish doctor shared a video about Verteporfin for hair loss. The conversation mentions Minoxidil, finasteride, and RU58841 as treatments.

Investing in pharmaceutical products to treat hair loss and the potential risks associated with that, as well as other treatments such as Minoxidil, Finasteride, RU58841, and a COVID-19 booster.

A user is asking about the effectiveness and dosage of RU58841 for hair loss, comparing it to Minoxidil and discussing its long-term use alongside Finasteride. They plan to use RU58841 and Finasteride for several years before potentially switching to GT20029.

A user is considering using topical finasteride, topical minoxidil, RU58841, and dermarolling twice a week to address hair loss after experiencing side effects with oral finasteride. They previously saw positive results with a topical spray containing finasteride, minoxidil, and tretinoin but discontinued use due to laziness.

Hair loss treatments like Dutasteride, RU58841, Finasteride, and Minoxidil are discussed, with skepticism about their effectiveness without photographic evidence. The conversation humorously critiques the reliance on anecdotal evidence for these treatments.

The conversation is about sourcing RU58841 for hair loss treatment in Australia and discusses the lack of effective alternatives. Alternatives mentioned include Kx826, fluridil, cb, alfatradiol, and topical spiro, but they are considered weak compared to RU58841.

Cyclosporine A is discussed as a powerful hair growth stimulant, potentially more effective than minoxidil, but concerns about safety and side effects, including cancer risk, limit its use. The conversation highlights the need for further research and experimentation with topical application, despite its risks.

CB-03-01 is a topical anti-androgen with low absorption, offering potential as a side-effect-free alternative to Finasteride/Dutasteride for hair loss. It's in stage 2 clinical trials for acne and showing promise for male pattern baldness.

PP405 is suspected to be a scam, with users doubting its legitimacy and effectiveness. Many recommend using proven treatments like finasteride and minoxidil.

The user experienced severe side effects from finasteride, including cognitive and sexual issues, despite its effectiveness for hair growth. They are considering switching to RU58841 and seek insights from others who have made a similar change.

Topical finasteride in Europe is often seen as less effective than oral forms, with users suggesting alternative application methods for better results. Many prefer oral finasteride due to cost and effectiveness.

FOL-005 claims to be more effective than Minoxidil and Finasteride but lacks anti-DHT properties, leading to potential reduced efficacy over time. Concerns are raised about misleading marketing and the safety of alternative treatments like Pyrilutamide and Clascoterone.

Switching to dutasteride as a hair loss prevention treatment, along with minoxidil, dermarolling and nizoral shampoo, and the potential benefits and side effects of using finasteride and/or dutasteride in combination with topical anti-androgens like RU58841.

Dutasteride and finasteride for hair loss, with dissatisfaction expressed about dutasteride and consideration of switching back to finasteride. Users share varied experiences, noting individual responses to treatments differ.

The user discusses using essential oils like peppermint, rosemary, tea tree, and lavender to improve hair thickness and seborrheic dermatitis. They plan to add RU58841 to their routine and seek advice on using it alongside the essential oils without interference.

The user is mixing various topical solutions for hair loss, including Dutasteride, Minoxidil, Finasteride, tretinoin, RU58841, Stemoxydine, and Reviv AHK-Cu, and is questioning if this practice is effective or wasteful. They are concerned about potential interactions, especially with the new treatment KX-826, which should not be mixed with Minoxidil.

GT20029 is a topical treatment that degrades androgen receptors to prevent hair thinning and loss, potentially offering fewer side effects than systemic treatments like finasteride. Concerns include its impact on hair texture and potential systemic effects, with market availability speculated in 3 to 5 years.

Treatments for hair loss, specifically discussing the use of RU58841 and Pyrilutamide from Actifolic. The poster is inquiring about experiences with these products and results.

Dutasteride is more effective than finasteride for hair loss, especially at the crown and midscalp, but both have similar side-effect profiles with low incidence of sexual adverse events. Improvement is measured visually, and significant results may take over 12 months to appear.

Finasteride can affect hormone levels within two weeks, and a break of several weeks is recommended for baseline results. Monitoring E2 and testosterone is suggested to assess the risk of gynecomastia.

User added RU58841 to their hair loss treatment and experienced quick results. Others also reported positive effects, but one user experienced chest pains as a side effect.

The conversation discusses Breezula, a hair loss treatment, and its Phase 3 clinical trial recruitment at 50 locations. Specific treatments mentioned include Minoxidil, Finasteride, and RU58841.

Treatment for hair loss, including Pyrilutamide, Minoxidil, Finasteride, and RU58841; with some users reporting success in growing vellus hairs.

People are discussing the potential benefits and drawbacks of a new time-release oral minoxidil (VDPHL01) for hair loss, with considerations about its cost, efficacy, and side effects compared to current treatments like 2.5mg doses and topical applications. Some users express interest in trying it if it proves effective and affordable, while others are cautious due to potential side effects or are satisfied with their current regimen.

Women experienced severe reactions, including Topical Steroid Withdrawal (TSW), from using Winlevi (Clascoterone 1%) on their faces. Concerns were raised about the potential risks of higher concentrations, especially for hair loss treatment.

A user's 11-month hair loss treatment progress using 0.5mg dutasteride every other day, 50mg RU58841 in the morning, 5mg oral minoxidil, topical minoxidil at night, and microneedling with a 1.5mm needle every other week. The user's improvement was significant, going from a severe hair loss stage (NW7) to a mild/moderate stage (NW2-3).

Minoxidil is highly toxic to pets, and there is a call for manufacturers to add a "Toxic to Pets" warning on packaging. A petition has been started to raise awareness and prevent pet fatalities.

The conversation discusses the potential of Sanguisorba Officinalis Root Extract as a treatment for hair loss by inhibiting FGF-5. The user also mentions the product évolis, which is based on this extract but is only available in the US and Australia.

Pelage is delaying the start of phase 3 trials for PP405 to 2026 due to necessary regulatory processes, despite having $120 million in funding. Users discuss the potential of PP405 for hair regrowth, with some expressing skepticism and others hopeful for new treatments like Breezula.

User used Finasteride, Dutasteride, and Minoxidil for one year to treat hair loss. They discussed possibly trying RU58841 or pyrilutamide in the future.